Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9455571 | 0.84 | PTK2 (0.62) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL466003 | 0.84 | RAB9A (0.46) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL11466907 | 0.84 | DEGS1 (0.56) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL17675503 | 0.82 | RAB9A (0.44) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL3720037 | 0.82 | RAB9A (0.44) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL3202851 | 0.82 | RAB9A (0.44) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL16246036 | 0.81 | RAB9A (0.43) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL8722614 | 0.81 | MEN1 (0.43) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL3925763 | 0.80 | KDR (0.47) | RAB9AL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL28322047 | 0.79 | RAB9A (0.50) | RAB9AMEN1KMT2AMAPTDEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| CN-102227420-B | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2015-06-24 | — | — | CN | disclosed |
| CN-104394869-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-04 | — | — | CN | disclosed |
| CN-102227420-A | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| EP-2344475-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2272826-A1 | 2-mercaptopentancarboxylic acid derivatives, the method for preparing them and the pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010149888-A1 | DERIVATIVES OF 2-MERCAPTOCYCLOPENTANE CARBOXYLIC ACID, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | LES LABORATOIRES SERVIER (FR) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | RAB9A 505/4885L3MBTL1 707/4885MEN1 83/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | RAB9A 1337/4885L3MBTL1 3823/4885MEN1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.